Eisai's LEQEMBI Shows Real-World Stability in 83% of Early Alzheimer’s Patients — Eisai Inc.

Event summary

Eisai’s LEQEMBI therapy stabilized or improved disease stages in 83% of early Alzheimer’s patients over an average of 17 months.
The real-world LEADER study included 432 patients across diverse U.S. clinical settings, with consistent results across sex, race, ethnicity, and APOE genotype.
Nearly 87% of patients chose to remain on LEQEMBI treatment, and safety observations aligned with FDA-approved labeling.
The study also evaluated maintenance dosing transitions, with 81% of IV maintenance patients remaining stable or improved.

The big picture

Eisai’s LEADER study results reinforce the strategic importance of real-world evidence in validating LEQEMBI’s efficacy beyond clinical trials. The findings come at a critical juncture as Eisai and Biogen aim to expand the drug’s global reach, particularly with the subcutaneous formulation approved in key markets like the U.S. and China. The consistent stability across diverse patient demographics underscores the potential for LEQEMBI to become a cornerstone therapy in early Alzheimer’s treatment.

What we're watching

Long-Term Efficacy: Whether LEQEMBI’s ability to stabilize or improve early Alzheimer’s patients will translate into sustained long-term benefits.
Regulatory Expansion: The pace at which Eisai and Biogen can secure approvals for LEQEMBI in additional countries, particularly with the subcutaneous formulation.
Market Adoption: How healthcare providers and patients will respond to the real-world data, potentially influencing broader adoption of LEQEMBI.